JP2004528307A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004528307A5 JP2004528307A5 JP2002573009A JP2002573009A JP2004528307A5 JP 2004528307 A5 JP2004528307 A5 JP 2004528307A5 JP 2002573009 A JP2002573009 A JP 2002573009A JP 2002573009 A JP2002573009 A JP 2002573009A JP 2004528307 A5 JP2004528307 A5 JP 2004528307A5
- Authority
- JP
- Japan
- Prior art keywords
- keto
- ketoalkanoic acid
- group
- mediated
- ketoalkanoic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 28
- 239000002253 acid Substances 0.000 claims 17
- 150000001875 compounds Chemical class 0.000 claims 10
- 230000004968 inflammatory condition Effects 0.000 claims 10
- 230000001404 mediated effect Effects 0.000 claims 8
- 102000004127 Cytokines Human genes 0.000 claims 7
- 108090000695 Cytokines Proteins 0.000 claims 7
- -1 acetoxymethyl Chemical group 0.000 claims 5
- 150000002148 esters Chemical class 0.000 claims 5
- 239000011575 calcium Substances 0.000 claims 4
- 239000012876 carrier material Substances 0.000 claims 4
- 150000001768 cations Chemical class 0.000 claims 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 3
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 150000001408 amides Chemical class 0.000 claims 3
- 229910052791 calcium Inorganic materials 0.000 claims 3
- 239000011777 magnesium Substances 0.000 claims 3
- XXRCUYVCPSWGCC-UHFFFAOYSA-N Ethyl pyruvate Chemical compound CCOC(=O)C(C)=O XXRCUYVCPSWGCC-UHFFFAOYSA-N 0.000 claims 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 2
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 claims 2
- 238000005837 enolization reaction Methods 0.000 claims 2
- 229940117360 ethyl pyruvate Drugs 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 229910052749 magnesium Inorganic materials 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 230000000087 stabilizing effect Effects 0.000 claims 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 claims 1
- TYEYBOSBBBHJIV-UHFFFAOYSA-N 2-oxobutanoic acid Chemical compound CCC(=O)C(O)=O TYEYBOSBBBHJIV-UHFFFAOYSA-N 0.000 claims 1
- XNIHZNNZJHYHLC-UHFFFAOYSA-N 2-oxohexanoic acid Chemical compound CCCCC(=O)C(O)=O XNIHZNNZJHYHLC-UHFFFAOYSA-N 0.000 claims 1
- KDVFRMMRZOCFLS-UHFFFAOYSA-N 2-oxopentanoic acid Chemical compound CCCC(=O)C(O)=O KDVFRMMRZOCFLS-UHFFFAOYSA-N 0.000 claims 1
- QHKABHOOEWYVLI-UHFFFAOYSA-N 3-methyl-2-oxobutanoic acid Chemical compound CC(C)C(=O)C(O)=O QHKABHOOEWYVLI-UHFFFAOYSA-N 0.000 claims 1
- BKAJNAXTPSGJCU-UHFFFAOYSA-N 4-methyl-2-oxopentanoic acid Chemical compound CC(C)CC(=O)C(O)=O BKAJNAXTPSGJCU-UHFFFAOYSA-N 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 102000003777 Interleukin-1 beta Human genes 0.000 claims 1
- 108090000193 Interleukin-1 beta Proteins 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 239000012891 Ringer solution Substances 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims 1
- 229940120503 dihydroxyacetone Drugs 0.000 claims 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 claims 1
- FJAKCEHATXBFJT-UHFFFAOYSA-N ethyl 2-oxobutanoate Chemical compound CCOC(=O)C(=O)CC FJAKCEHATXBFJT-UHFFFAOYSA-N 0.000 claims 1
- WRQGPGZATPOHHX-UHFFFAOYSA-N ethyl 2-oxohexanoate Chemical compound CCCCC(=O)C(=O)OCC WRQGPGZATPOHHX-UHFFFAOYSA-N 0.000 claims 1
- YERWBBMSDMSDKT-UHFFFAOYSA-N ethyl 2-oxopentanoate Chemical compound CCCC(=O)C(=O)OCC YERWBBMSDMSDKT-UHFFFAOYSA-N 0.000 claims 1
- CKTYYUQUWFEUCO-UHFFFAOYSA-N ethyl 3-methyl-2-oxobutanoate Chemical compound CCOC(=O)C(=O)C(C)C CKTYYUQUWFEUCO-UHFFFAOYSA-N 0.000 claims 1
- MGSWAHQQBHNCEI-UHFFFAOYSA-N ethyl 4-methyl-2-oxopentanoate Chemical compound CCOC(=O)C(=O)CC(C)C MGSWAHQQBHNCEI-UHFFFAOYSA-N 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 229910001414 potassium ion Inorganic materials 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- FPOLWERNILTNDK-UHFFFAOYSA-N pyruvamide Chemical compound CC(=O)C(N)=O FPOLWERNILTNDK-UHFFFAOYSA-N 0.000 claims 1
- 229940107700 pyruvic acid Drugs 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 239000012266 salt solution Substances 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 102000003390 tumor necrosis factor Human genes 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27627901P | 2001-03-15 | 2001-03-15 | |
| PCT/US2002/008283 WO2002074301A1 (en) | 2001-03-15 | 2002-03-15 | Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004528307A JP2004528307A (ja) | 2004-09-16 |
| JP2004528307A5 true JP2004528307A5 (enExample) | 2005-12-22 |
Family
ID=23055992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002573009A Pending JP2004528307A (ja) | 2001-03-15 | 2002-03-15 | サイトカインにより媒介される炎症性状態の治療のためのピルベートおよび／またはその誘導体の使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US6943190B2 (enExample) |
| EP (1) | EP1379230A4 (enExample) |
| JP (1) | JP2004528307A (enExample) |
| AU (1) | AU2002255805B2 (enExample) |
| CA (1) | CA2440480A1 (enExample) |
| WO (1) | WO2002074301A1 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6303321B1 (en) | 1999-02-11 | 2001-10-16 | North Shore-Long Island Jewish Research Institute | Methods for diagnosing sepsis |
| WO2002074301A1 (en) * | 2001-03-15 | 2002-09-26 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions |
| AU2002254525B2 (en) * | 2001-04-04 | 2004-12-23 | Critical Therapeutics, Inc. | Method for preventing acute renal failure |
| EP1392639B1 (en) | 2001-05-03 | 2008-09-17 | Galileo Laboratories, Inc. | Pyruvate derivatives |
| US7304034B2 (en) | 2001-05-15 | 2007-12-04 | The Feinstein Institute For Medical Research | Use of HMGB fragments as anti-inflammatory agents |
| US8076373B2 (en) * | 2001-09-11 | 2011-12-13 | North Cell Pharmacetical | Method for treating mammalian diseases and injuries caused by the over-expression of peroxynitrite |
| US7122578B2 (en) * | 2001-09-11 | 2006-10-17 | Alain Martin | Method and composition for treating mammalian diseases and injuries which cause pain, erythema, swelling, crusting, ischemia scarring and excess white blood cell infiltration |
| DE60326453D1 (de) * | 2002-07-03 | 2009-04-16 | Ct Cardiologico Monzino S P A | Die verwendung von hmgb1 zur behandlung von gewebeverletzungen und/oder zur unterstützung der gewebewiederherstellung |
| CN102657651A (zh) * | 2002-12-06 | 2012-09-12 | 范因斯坦医学研究院 | 用α 7受体结合胆碱能激动剂抑制炎症 |
| US7696169B2 (en) | 2003-06-06 | 2010-04-13 | The Feinstein Institute For Medical Research | Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents |
| WO2005004857A1 (en) * | 2003-06-09 | 2005-01-20 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Method for treating acute pancreatitis |
| US20050032891A1 (en) * | 2003-06-13 | 2005-02-10 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Method for treating alcoholic hepatitis |
| ES2222093A1 (es) * | 2003-07-01 | 2005-01-16 | Advanced In Vitro Cell Technologies, S.L. | Metodo para el almacenamiento y/o transporte de cultivos celulares in vitro. |
| WO2005026209A2 (en) | 2003-09-11 | 2005-03-24 | Critical Therapeutics, Inc. | Monoclonal antibodies against hmgb1 |
| CN1997897A (zh) * | 2003-10-24 | 2007-07-11 | 梅德特龙尼克有限公司 | 通过削弱促炎介质的产生治疗神经病症的技术 |
| EP1814576A2 (en) * | 2004-07-20 | 2007-08-08 | Critical Therapeutics, Inc. | Combination therapies of hmgb and complement inhibitors against inflammation |
| US20060253100A1 (en) | 2004-10-22 | 2006-11-09 | Medtronic, Inc. | Systems and Methods to Treat Pain Locally |
| WO2006108682A2 (en) * | 2005-04-15 | 2006-10-19 | Biomac Privatinstitut Für Medizinische Und Zahnmedizinische Forschung, Entwicklung Und Diagnostik Gmbh | Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use as anti-fungal agents |
| EP1909834A2 (en) * | 2005-07-18 | 2008-04-16 | Critical Therapeutics, Inc. | Use of hmgb1 antagonists for the treatment of inflammatory skin conditions |
| CN101472613A (zh) * | 2006-04-12 | 2009-07-01 | R·L·亚历山大 | 包含丙酮酸烷基酯的组合物及其应用 |
| US7754247B2 (en) * | 2007-05-29 | 2010-07-13 | University Of South Carolina | Resuscitation fluid |
| US8114907B2 (en) * | 2007-08-08 | 2012-02-14 | Cellular Sciences Inc | Method for treating a pulmonary disease state in mammals by up regulating indigenous in vivo levels of inflammatory agents in mammalian cells |
| US8211943B2 (en) * | 2007-08-08 | 2012-07-03 | Alain Martin | Method for treating a pulmonary disease state in mammals by up regulating indigenous in vivo levels of inflammatory agents in mammalian cells |
| US8815946B2 (en) * | 2008-01-25 | 2014-08-26 | University of Pittsburgh—of the Commonwealth System of Higher Education | Inhibition of proliferation and fibrotic response of activated corneal stromal cells |
| JP5630750B2 (ja) * | 2008-03-18 | 2014-11-26 | 国立大学法人 岡山大学 | 興奮性化学伝達調節剤およびそのスクリーニング法 |
| USRE48948E1 (en) | 2008-04-18 | 2022-03-01 | Warsaw Orthopedic, Inc. | Clonidine compounds in a biodegradable polymer |
| US8445717B2 (en) * | 2008-11-20 | 2013-05-21 | Chd Bioscience, Inc. | α-Keto alkylperacids and methods for producing and using the same |
| ES2492497T3 (es) * | 2008-11-20 | 2014-09-09 | Chd Bioscience, Inc. | Perácidos alfa-ceto y métodos para su producción y uso |
| DK2367549T3 (da) | 2008-12-30 | 2013-11-04 | Hills Pet Nutrition Inc | Anvendelse af alfalipoinsyre til behandling eller forebyggelse af nedbrydende ledsygdomme, osteoarthritis, bruskskade, og relaterede lidelser hos kæledyr |
| US20100239632A1 (en) | 2009-03-23 | 2010-09-23 | Warsaw Orthopedic, Inc. | Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue |
| CA2785641C (en) | 2009-12-29 | 2014-11-25 | Hill's Pet Nutrition, Inc. | Compositions including pyruvate for companion animals and methods of use thereof |
| US11284621B2 (en) | 2010-04-15 | 2022-03-29 | Armis Biopharma, Inc. | Compositions comprising peroxyacid and methods for producing and using the same |
| US9044527B2 (en) | 2011-02-17 | 2015-06-02 | Chd Bioscience, Inc. | Wound care products with peracid compositions |
| JP6291256B2 (ja) * | 2011-02-17 | 2018-03-14 | シーエイチディー・バイオサイエンス，インコーポレーテッド | ペルオキシα−ケトカルボン酸を含む組成物、および該組成物を産生し、そして用いるための方法 |
| CN103228290A (zh) * | 2011-02-18 | 2013-07-31 | (株)斯坦帝尔 | 包含沉默信息调节因子1表达诱导物质的败血症或者败血性休克的预防或者治疗用组合物 |
| US9244074B2 (en) * | 2011-06-07 | 2016-01-26 | University Of Hawaii | Biomarker of asbestos exposure and mesothelioma |
| WO2012170742A2 (en) | 2011-06-07 | 2012-12-13 | University Of Hawaii | Treatment and prevention of cancer with hmgb1 antagonists |
| WO2014063115A1 (en) | 2012-10-18 | 2014-04-24 | Chd Bioscience, Inc. | Compositions comprising peroxy acid |
| US9578879B1 (en) | 2014-02-07 | 2017-02-28 | Gojo Industries, Inc. | Compositions and methods having improved efficacy against spores and other organisms |
| DE102017131059A1 (de) * | 2017-12-22 | 2019-06-27 | Christiane Kappert | Physiologisch verträgliche Lösung mit einem Gehalt an Pyruvat und Glycin, eine Pyruvat und Glycin enthaltende Zusammensetzung und Verfahren zu deren Herstellung |
| EP3797766A1 (en) * | 2019-09-24 | 2021-03-31 | Evonik Operations GmbH | Compositions for use in reducing inflammation |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2307075A (en) * | 1940-08-02 | 1943-01-05 | Carbide And Carbon Chemicais C | Vinyl resin composition |
| US4105782A (en) * | 1975-03-07 | 1978-08-08 | Yu Ruey J | Treatment of acne and dandruff |
| US4197316A (en) * | 1975-07-23 | 1980-04-08 | Scott Eugene J Van | Treatment of dry skin |
| JPS539847A (en) * | 1976-07-15 | 1978-01-28 | Akishima Kagaku Kogyo | Stabilized halogenncontained resin composition |
| US4234599A (en) * | 1978-10-04 | 1980-11-18 | Scott Eugene J Van | Treatment of skin keratoses with α-hydroxy acids and related compounds |
| US4246261A (en) * | 1979-08-09 | 1981-01-20 | Scott Eugene J Van | Additives enhancing topical corticosteroid action |
| DE3133132A1 (de) * | 1981-08-21 | 1983-03-03 | Schweiger Hubert | Terpene in synergistisch wirkenden kombinationen mit (alpha)-ketomono- und/oder (alpha)-ketodicarbonsaeuren und/oder deren mono- bzw. mono- und/oder diester und verwendung dieser pflanzlichen wirkstoffkombinationen als bioaktive mittel in arznei-, kosmetischen und dermatologischen mitteln |
| DE3581407D1 (de) | 1985-09-06 | 1991-02-21 | Nestle Sa | Bewahrung lebender gewebe. |
| US6051609A (en) | 1997-09-09 | 2000-04-18 | Tristrata Technology, Inc. | Additives enhancing the effect of therapeutic agents |
| US5210098A (en) | 1990-09-21 | 1993-05-11 | Regents Of The University Of Minnesota | Use of pyruvate to treat acute renal failure |
| WO1992004826A1 (en) * | 1990-09-21 | 1992-04-02 | Regents Of The University Of Minnesota | Pyruvate solutions to counteract acute renal failure |
| US5648380A (en) | 1991-03-01 | 1997-07-15 | Warner-Lambert Company | Anti-inflammatory wound healing compositions and methods for preparing and using same |
| WO1993006726A1 (en) | 1991-09-30 | 1993-04-15 | Mackenzie Walser | Methods for treatment of free-radical-mediated tissue injury |
| DE4415581C2 (de) * | 1994-05-04 | 1995-12-07 | Voith Gmbh J M | Papier-Streichvorrichtung |
| US5536751A (en) * | 1994-05-09 | 1996-07-16 | The United States Of America As Represented By The Secretary Of The Army | Pharmaceutical alpha-keto carboxylic acid compositions method of making and use thereof |
| US5480909A (en) | 1994-08-08 | 1996-01-02 | University Of Pittsburgh Medical Center | Method for inhibiting generation of free-radicals |
| US5908611A (en) | 1995-05-05 | 1999-06-01 | The Scripps Research Institute | Treatment of viscous mucous-associated diseases |
| AU719332B2 (en) * | 1995-09-19 | 2000-05-04 | Cellular Sciences, Inc. | Method and composition for treating mammalian diseases caused by inflammatory response |
| US5798388A (en) * | 1996-09-06 | 1998-08-25 | Cellular Sciences, Inc. | Method and composition for treating mammalian diseases caused by inflammatory response |
| US6086789A (en) * | 1996-03-18 | 2000-07-11 | Case Western Reserve University | Medical uses of pyruvates |
| US5756469A (en) | 1996-07-26 | 1998-05-26 | Beale; Paxton K. | Composition of pyruvate and anti-cortisol compounds and method for increasing protein concentration in a mammal |
| US6417231B1 (en) * | 1996-12-23 | 2002-07-09 | Frank L. Greenway | Method and composition for delivering therapeutically effective amounts of pyruvate to a mammal |
| CA2373611C (en) | 1999-05-14 | 2009-06-23 | Cellular Sciences, Inc. | Method and composition for treating mammalian nasal and sinus diseases caused by inflammatory response |
| US6846842B2 (en) * | 1999-10-07 | 2005-01-25 | Beth Israel Deconess Medical Center, Inc. | Pyruvate ester composition and method of use for resuscitation after events of ischemia and reperfusion |
| DE60027319T2 (de) * | 1999-10-07 | 2007-04-05 | Xanthus Life Sciences, Inc., Montreal | Pyruvatesterzusammenstellung und verwendungsmethode zur wiederbelebung nach ischemie- und reperfusionsvorfällen |
| WO2002074301A1 (en) * | 2001-03-15 | 2002-09-26 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions |
-
2002
- 2002-03-15 WO PCT/US2002/008283 patent/WO2002074301A1/en not_active Ceased
- 2002-03-15 EP EP02725226A patent/EP1379230A4/en not_active Withdrawn
- 2002-03-15 AU AU2002255805A patent/AU2002255805B2/en not_active Ceased
- 2002-03-15 CA CA002440480A patent/CA2440480A1/en not_active Abandoned
- 2002-03-15 JP JP2002573009A patent/JP2004528307A/ja active Pending
-
2003
- 2003-09-15 US US10/662,975 patent/US6943190B2/en not_active Expired - Fee Related
-
2005
- 2005-03-31 US US11/095,031 patent/US20050245609A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004528307A5 (enExample) | ||
| JP2004501189A5 (enExample) | ||
| CN1088992C (zh) | 治疗眼炎的含3－苯甲酰基苯乙酸衍生物的局部给药组合物 | |
| JP3778516B2 (ja) | 新規なアリールプロピオン酸誘導体、その製造方法及び鎮痛薬としてのその用途 | |
| RU2003135482A (ru) | Геропротектор на основе гидрированных пиридо(4,3-b) индолов (варианты), фармакологическое средство на его основе и способ его применения | |
| JP2011510080A5 (enExample) | ||
| JP2012521429A5 (enExample) | ||
| JP2004516314A5 (enExample) | ||
| RU2006105804A (ru) | Нитрооксипроизводные лозартана, валсартана, кандесартана, телмисартана, эпросартана и олмесартана в качестве блокаторов рецепторов ангиотензина ii для лечения сердечно-сосудистых заболеваний | |
| RU2003103286A (ru) | Ингибиторы медьсодержащих аминооксидаз | |
| RU2008109914A (ru) | Применение производных тиенопиридона в качестве активаторов амфк и фармацевтические композиции, которые их содержат | |
| RU99110944A (ru) | Тиенопиримидины с ингибирующим действием по отношению к фосфодиэстеразе v (pde v) | |
| JP2009530398A5 (enExample) | ||
| JP2011507896A5 (enExample) | ||
| RU2004134604A (ru) | Тетрагидропиранилциклопентилтерагидропиридопиридиновые модуляторы активности рецептора хемокина | |
| RU2005128501A (ru) | Соединение для лечения метаболических расстройств | |
| RU2000116899A (ru) | Тиенопиримидины | |
| JP2005527592A5 (enExample) | ||
| CA2522738A1 (en) | Compounds for the treatment of metabolic disorders | |
| CA2521621A1 (en) | Compounds for the treatment of metabolic disorders | |
| EP1494659B1 (en) | Pharmaceutical composition comprising an alpha-ketoalkanoic acid ester or -amide and lactic acid or a lactic acid salt | |
| EP2941252A2 (en) | Use of fatty acid niacin conjugates for treating diseases | |
| JP2007501800A5 (enExample) | ||
| RU2000129659A (ru) | Конденсированные тиенопиримидины с ингибирующим фосфодиэстеразу v действием | |
| RU96123227A (ru) | Амидные производные и их терапевтическое использование |